import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: 'vilon-peptide-immune-research',
  title: 'Vilon: The Dipeptide Studied for Immune Regulation and Longevity',
  description:
    'A research overview of Vilon (Lys-Glu), the synthetic dipeptide from the Khavinson peptide bioregulator series studied for immune system modulation, thymic restoration, and longevity endpoints in preclinical and clinical models.',
  category: 'Compound Profiles',
  readMinutes: 9,
  publishedAt: '2026-06-12',
  ogImage: '/og-image.jpg',
  body: [
    {
      type: 'callout',
      text: 'All content is for research reference only. Vilon is a research compound. Nothing herein constitutes medical advice or a recommendation for human use.',
    },
    {
      type: 'paragraph',
      text: 'Vilon (chemical structure: Lys-Glu; lysyl-glutamic acid) is a synthetic dipeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson, one of the primary architects of the peptide bioregulator research tradition. Unlike larger peptides in the Khavinson series (Thymalin, Epithalon, Cortagen), Vilon is a minimal two-amino-acid sequence designed to retain the immunomodulatory activity of thymic peptide fractions while achieving complete chemical synthesis and regulatory simplicity.',
    },
    {
      type: 'paragraph',
      text: 'The Khavinson peptide bioregulator program began in the 1970s as a Soviet military and gerontology initiative to develop organ-specific peptide preparations from tissue extracts — with the hypothesis that each tissue type releases short regulatory peptides that act as paracrine and autocrine signals for that tissue\'s homeostasis. Vilon was developed as the synthetic minimal active fragment of thymic tissue extracts, and its research profile reflects that origin: primary documented activity in immune system regulation, with secondary data on longevity extension in model organisms.',
    },
    {
      type: 'heading',
      text: 'Mechanism of Action: Thymic Peptide Biology',
    },
    {
      type: 'paragraph',
      text: 'The thymus gland is the primary site of T-cell maturation and a major source of immunomodulatory peptides. Thymic involution — the progressive atrophy of the thymus with age — is a well-documented driver of immunosenescence: the age-related decline in immune competence that underlies increased infection susceptibility, reduced vaccine response, and elevated autoimmune dysregulation in older organisms.',
    },
    {
      type: 'paragraph',
      text: 'Vilon\'s proposed mechanism centers on the dipeptide Lys-Glu acting as a minimal thymic signal capable of restoring thymic peptide-dependent immune programs in conditions of thymic insufficiency. Research has documented effects on:',
    },
    {
      type: 'list',
      items: [
        'T-lymphocyte differentiation and proliferation: Enhanced CD3+ T-cell responses in aged animal models',
        'NK cell activity: Upregulation of natural killer cell cytotoxicity in immunosenescent models',
        'Cytokine balance: Modulation of IL-2 and interferon-gamma, pro-thymic T-cell cytokines',
        'Thymus-dependent antibody responses: Improvement in T-cell-dependent humoral immunity',
        'Bone marrow progenitor cell activity: Indirect effects on T-cell precursor output from bone marrow',
      ],
    },
    {
      type: 'paragraph',
      text: 'At the molecular level, Vilon (Lys-Glu) is hypothesized to interact with cell surface receptors on thymic epithelial cells and T-lymphocyte precursors, mimicking the signal provided by larger thymic hormones (thymosin alpha-1, thymulin, thymopoietin). The dipeptide\'s extreme simplicity suggests it acts as a minimal pharmacophore — the smallest sequence sufficient to trigger downstream thymic regulatory programs.',
    },
    {
      type: 'heading',
      text: 'Longevity Research: Key Findings',
    },
    {
      type: 'paragraph',
      text: 'Vilon has been studied in the context of organismal lifespan extension, primarily in invertebrate models. The most cited data from the Khavinson group documents significant mean and maximum lifespan extension in Drosophila melanogaster (fruit fly) models — with reported effects in the 20–30% range for mean lifespan extension in some experimental conditions. Similar data has been published for Vilon in Ceriodaphnia affinis (water flea) models, a standard short-generation longevity research platform.',
    },
    {
      type: 'paragraph',
      text: 'In rodent models, Vilon has been studied for effects on age-related pathology rather than raw lifespan extension. Published findings include reductions in spontaneous tumor incidence in aged mice, improvements in bone marrow cellularity (relevant to immune progenitor output), and preservation of thymus weight with treatment compared to untreated aged controls. These data points fit a consistent mechanistic picture: Vilon slows immune system aging, and reduced immunosenescence produces downstream benefits in tumor surveillance and infection resistance that contribute to improved healthspan.',
    },
    {
      type: 'subheading',
      text: 'Human Research Context',
    },
    {
      type: 'paragraph',
      text: 'Unlike most research peptides where human data is essentially absent, Vilon (as part of the Khavinson peptide bioregulator program) has been administered in Russian clinical research contexts, particularly in elderly populations and clinical settings focused on immune reconstitution. Published clinical data — primarily from Russian and Eastern European journals — reports improvements in T-lymphocyte populations, reduced infection rates in immunocompromised patients, and improvements in various age-related immune markers in geriatric cohorts. These studies have methodological limitations common to this literature (small sample sizes, open-label designs, variable endpoint standardization) but represent a level of human context data that most peptide research compounds lack.',
    },
    {
      type: 'heading',
      text: 'Comparison to Other Thymic Peptides',
    },
    {
      type: 'table',
      headers: ['Peptide', 'Size', 'Origin', 'Primary Research Application', 'Human Data'],
      rows: [
        ['Vilon (Lys-Glu)', '2 AA', 'Synthetic', 'Immune modulation, longevity extension', 'Limited clinical series (Russia)'],
        ['Thymalin', 'Polypeptide extract', 'Thymus extract', 'Immune restoration, anti-aging', 'Extensive Russian clinical data'],
        ['Thymosin Alpha-1', '28 AA', 'Synthetic', 'Antiviral, immune activation', 'FDA-approved equivalent (Zadaxin) in some regions'],
        ['Thymosin Beta-4 (TB-500)', '43 AA', 'Synthetic', 'Tissue repair, wound healing, cardiac', 'Preclinical; limited human exposure data'],
        ['Thymulin (Facteur Thymique Sérique)', '9 AA', 'Endogenous zinc-dependent', 'T-cell differentiation research', 'Research tool primarily'],
      ],
    },
    {
      type: 'paragraph',
      text: 'Vilon occupies a unique niche: it is the most structurally minimal thymic peptide bioregulator, which confers advantages in chemical stability and synthetic accessibility, but limits the range of receptor interactions and signaling complexity compared to larger thymic peptides. Thymosin Alpha-1 has the most robust international clinical evidence base; Thymalin has the deepest Russian clinical history; Vilon has the best longevity model data and the simplest structure.',
    },
    {
      type: 'heading',
      text: 'Research Protocol Considerations',
    },
    {
      type: 'paragraph',
      text: 'Vilon research protocols in the published literature use the following parameters as reference points:',
    },
    {
      type: 'list',
      items: [
        'Route: Subcutaneous injection is most commonly reported; some studies use oral administration in invertebrate models',
        'Dose (rodent): 0.5–10 µg/kg/day, typically at the lower end of this range',
        'Frequency: Daily or every-other-day injections in most published protocols',
        'Duration: 2–12 weeks for immune endpoint studies; longer for lifespan studies',
        'Key endpoints: Flow cytometry for T-cell subpopulations (CD3, CD4, CD8, NK), thymus weight and histology, cytokine assays (IL-2, IFN-γ), NK cytotoxicity assays',
      ],
    },
    {
      type: 'heading',
      text: 'Sourcing Quality Standards',
    },
    {
      type: 'paragraph',
      text: 'As a dipeptide, Vilon (Lys-Glu) is among the most straightforward peptides to synthesize and verify analytically. Quality criteria for research use:',
    },
    {
      type: 'list',
      items: [
        'HPLC purity ≥98% — dipeptide purity is straightforward to verify; accept no COA without the chromatogram',
        'MS confirmation — MW of Lys-Glu is approximately 275 Da; easily confirmed by any modern mass spectrometry',
        'LAL endotoxin testing — particularly relevant for immune research where contamination directly confounds endpoints',
        'Lot-specific documentation — not batch-pooled COAs',
        'Lyophilized form preferred for stability; avoid pre-dissolved preparations unless same-day use',
      ],
    },
    {
      type: 'heading',
      text: 'Summary',
    },
    {
      type: 'paragraph',
      text: 'Vilon is among the most minimal peptides in the longevity research toolkit: a two-amino-acid sequence with documented effects on immune system aging, T-lymphocyte biology, and lifespan extension in model organisms. Its position within the Khavinson peptide bioregulator tradition means it carries more human research context than most peptide research compounds, though that data has significant methodological limitations. For researchers studying immunosenescence, thymic restoration, or longevity biology, Vilon offers a structurally tractable tool with a coherent mechanistic foundation and an unusually broad evidence base for a research-stage compound.',
    },
    {
      type: 'disclaimer',
      text: 'For research purposes only. Not intended for human use. These statements have not been evaluated by the FDA.',
    },
  ],
};
